List view / Grid view

Alzheimer's

27 Phase III and 8 Phase II Alzheimer’s drugs on track to launch in next 5 years

19 July 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years...

news

Study predicts 1.2 million people in UK will be living with dementia by 2040

5 July 2017 | By Niamh Marriott (European Pharmaceutical Review)

By 2040, there will be over 1.2 million people living with dementia in England and Wales (an increase of 57% from 2016), due to increased life expectancy...

news

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

23 August 2016 | By AstraZeneca

AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.

news

FDA approves expanded label for Namzaric in Alzheimer’s disease

20 July 2016 | By Victoria White, Digital Content Producer

The US Food and Drug Administration (FDA) has approved an expanded label for Namzaric.

news

Trial of RVT-101 in Alzheimer’s disease starts at Plymouth Science Park

11 July 2016 | By Victoria White, Digital Content Producer

If approved, RVT-101 could be the first Alzheimer’s treatment in 14 years. The last drug to be approved to help improve cognition was Donepezil in 2002...

news

Investigational Alzheimer’s treatment Aducanumab accepted into EMA’s PRIME programme

2 June 2016 | By Victoria White, Digital Content Producer

PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines...

news

Phase II/III trial of AZD3293 in early Alzheimer’s disease to continue

8 April 2016 | By Victoria White

AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial...

news

Lilly changes the primary endpoint of the EXPEDITION3 Alzheimer’s trial

15 March 2016 | By Victoria White

Lilly has made a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's dementia...

news

Alzheimer’s disease treatment market to more than double by 2021, says GBI Research

11 February 2016 | By Victoria White

GBI Research says the impressive growth in the treatment market will be primarily driven by increased disease prevalence during the forecast period...

article

European Pharmaceutical Review’s top 10 stories from 2015

28 January 2016 | By Victoria White (European Pharmaceutical Review)

Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.

news

Aridhia’s data platform selected by EPAD for dementia prevention project

19 January 2016 | By Victoria White

The EPAD project is a powerful research collaboration between European organisations in the public and private sectors which focuses on prevention of dementia in the early stages of the disease...

news

MHRA helps make dementia medicine packaging more user-friendly

4 November 2015 | By Victoria White

From June 2016, medicines for the treatment of dementia will include the days of the week clearly on the blister packs...

news

Donepezil may delay residential care for Alzheimer’s sufferers

27 October 2015 | By Victoria White

Withdrawing donepezil from people in the advanced stages of Alzheimer's disease doubles their risk of being placed in a nursing home within a year, according to a UCL study...

news

Resveratrol stabilises Alzheimer’s disease biomarker

14 September 2015 | By Victoria White

Patients who were treated with increasing doses of resveratrol over 12 months showed little or no change in amyloid-beta40 (Abeta40) levels...

news

First patient enrolled in Phase 3 study of aducanumab in Alzheimer’s

8 September 2015 | By Victoria White

Biogen's Phase 3 programme includes two global studies designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Alzheimer's